Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medmelior Inc. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is localized to 1 distinct examiner and 1 distinct art unit, which points to a very specific technical focus for the current portfolio. Such a concentrated presence suggests that the company's immediate intellectual property interests are being evaluated within a single specialized regulatory framework. The focus on a single art unit indicates that the technology is being compared against a narrow field of prior art.
The busiest examiner, DABKOWSKI, ERINNE R, is responsible for 1 pending office action. This single examiner manages the full extent of the company's current pending matters. Consequently, the prosecution strategy must be tailored specifically to the precedents and preferences of this individual. The presence of only 1 art unit further confirms that the current legal challenges are limited to a specific area of biotechnology. For the practitioner, this means that the relationship with DABKOWSKI, ERINNE R is the primary factor in the advancement of the current portfolio. There is no distribution of risk across other examiners, making this a highly centralized prosecution effort.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17235654 | RECOMBINANT INTERFERON | DABKOWSKI, ERINNE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17235654 | RECOMBINANT INTERFERON | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17235654 | RECOMBINANT INTERFERON | DABKOWSKI, ERINNE R | 1654 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedmelior Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erinne R Dabkowski has the most, with 1 of Medmelior Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
